SCHEMBL13199240

SCHEMBL13199240

Cc1cc(OCc2ccccc2)cc(OCc2ccccc2)c1C(=O)NNC(=O)Cc1cccc(O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ PDCD1 Q15116 1/20 0.42
▸ CD274 Q9NZQ7 1/20 0.42
▸ PLAU P00749 1/20 0.42
▸ ELANE P08246 1/20 0.42
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ SMPD1 P17405 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ FFAR1 O14842 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ NCOA2 Q15596 1/20 0.40
▸ NCOA1 Q15788 1/20 0.40
▸ NCOA3 Q9Y6Q9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951993 0.92 SMPD1 (0.44) PDCD1CD274PLAUELANESMPD1
SCHEMBL13199254 0.87 SMPD1 (0.43) GAASMN1; SMN2PLAUELANESMPD1
SCHEMBL2951787 0.86 KEAP1 (0.41) GAASMN1; SMN2PDCD1CD274PLAU
SCHEMBL2969572 0.82 MRGPRX4 (0.40) SMN1; SMN2MRGPRX4SMPD1FFAR1MEN1
SCHEMBL2956660 0.81 MAPT (0.51) GAASMN1; SMN2MRGPRX4SMPD1FFAR1
SCHEMBL13199138 0.79 NPC1 (0.51) GAASMN1; SMN2PDCD1CD274PLAU
SCHEMBL13199109 0.78 PLAU (0.61) SMN1; SMN2MRGPRX4PLAUELANEMEN1
SCHEMBL13214887 0.78 KDM4E (0.44) SMN1; SMN2PLAUELANEMEN1KMT2A
SCHEMBL2957817 0.78 LMNA (0.52) GAASMN1; SMN2PDCD1CD274PLAU
SCHEMBL1842000 0.78 MEN1 (0.56) MRGPRX4FFAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 — — US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 — — US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 — — EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 — — US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 GAA 1381/4885SMN1; SMN2 4782/4885MRGPRX4 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback